News Image

Why the dividend investor may take a look at NASDAQ:SNY.

By Mill Chart

Last update: Feb 14, 2024

Our stock screener has spotted SANOFI-ADR (NASDAQ:SNY) as a good dividend stock with solid fundamentals. NASDAQ:SNY shows decent health and profitability. At the same time it gives a good and sustainable dividend. We'll dive into each aspect below.

What does the Dividend looks like for NASDAQ:SNY

To gauge a stock's dividend quality, ChartMill utilizes a Dividend Rating ranging from 0 to 10. This comprehensive assessment considers various dividend aspects, including yield, history, growth, and sustainability. NASDAQ:SNY has achieved a 8 out of 10:

  • With a Yearly Dividend Yield of 4.15%, SNY is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 4.43, SNY pays a better dividend. On top of this SNY pays more dividend than 95.54% of the companies listed in the same industry.
  • SNY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.49.
  • SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • SNY pays out 35.10% of its income as dividend. This is a sustainable payout ratio.
  • SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.

Health Analysis for NASDAQ:SNY

ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:SNY, the assigned 5 for health provides valuable insights:

  • SNY has an Altman-Z score of 3.06. This indicates that SNY is financially healthy and has little risk of bankruptcy at the moment.
  • SNY has a better Altman-Z score (3.06) than 77.72% of its industry peers.
  • SNY has a debt to FCF ratio of 2.59. This is a good value and a sign of high solvency as SNY would need 2.59 years to pay back of all of its debts.
  • The Debt to FCF ratio of SNY (2.59) is better than 91.09% of its industry peers.
  • A Debt/Equity ratio of 0.22 indicates that SNY is not too dependend on debt financing.

Evaluating Profitability: NASDAQ:SNY

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:SNY, the assigned 7 is noteworthy for profitability:

  • SNY has a better Return On Assets (10.12%) than 94.06% of its industry peers.
  • The Return On Equity of SNY (17.47%) is better than 92.08% of its industry peers.
  • SNY has a Return On Invested Capital of 15.53%. This is amongst the best in the industry. SNY outperforms 92.57% of its industry peers.
  • The 3 year average ROIC (6.95%) for SNY is below the current ROIC(15.53%), indicating increased profibility in the last year.
  • With an excellent Profit Margin value of 18.09%, SNY belongs to the best of the industry, outperforming 93.56% of the companies in the same industry.
  • SNY has a Operating Margin of 27.75%. This is amongst the best in the industry. SNY outperforms 94.06% of its industry peers.
  • SNY's Operating Margin has improved in the last couple of years.
  • SNY has a Gross Margin of 70.31%. This is in the better half of the industry: SNY outperforms 78.22% of its industry peers.

More Best Dividend stocks can be found in our Best Dividend screener.

Our latest full fundamental report of SNY contains the most current fundamental analsysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

SANOFI-ADR

NASDAQ:SNY (5/17/2024, 7:00:03 PM)

After market: 48.67 0 (0%)

48.67

-0.15 (-0.31%)

SNY News

News Imagea day ago - The Motley FoolCould Novavax Become the Next Moderna?

Sanofi believes in Novavax's vaccine strengths...

News Image3 days ago - InvestorPlace3 Stocks Under $2 That Can Trade in Double Digits by 2025

These stocks under $2 are likely to surge higher as they represent companies with impending growth catalysts.

News Image3 days ago - BusinessInsider3 Stocks Under $2 That Can Trade in Double Digits by 2025

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors tend to be interested in low-priced stocks. A probable reason is havi...

News Image3 days ago - The Motley FoolNovavax Stock Just Tripled. Is It Too Late to Buy?

Novavax shares have soared and plummeted in recent years.

News Image4 days ago - InvestorPlace3 Cheap Biotech Stocks to Buy Now: May 2024

Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market.

News Image4 days ago - InvestorPlace3 Meme Stocks That Are Likely to Crater in 2024

These are the meme stocks to avoid as they represent fundamentally weak companies with a sluggish growth outlook.

News Image5 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

News Image5 days ago - Fulcrum Therapeutics, Inc.Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
News Image5 days ago - Fulcrum Therapeutics, Inc.Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
News Image5 days ago - Regeneron Pharmaceuticals, Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
News Image8 days ago - The Motley FoolWhy Novavax Stock More Than Doubled Today

A cloud of doubt hanging over the company just gave way to some sunshine.

News Image8 days ago - InvestorPlaceNVAX Stock Alert: Novavax Just Hit a New 52-Week High

Novavax stock is heading higher on Friday as NVAX investors celebrate it reaching a new 52-week high following a deal with Sanofi.

SNY Links
Follow us for more